(in Patients with pre-existing CAD) Copeptin + cTnT: sensitivity 98.7% (93.0–99.8), specificity 53.5% (48.2–58.8), NPV 99.5% (97.1–99.9), PPV 31.8% (26.0–38.1). Copeptin + hs-cTnT: sensitivity 98.7% (93.0–99.8), specificity 41.4% (36.2–46.7), NPV 99.3% (96.3–99.9), PPV 27.0% (22.0–32.6). This evidence concerns the gene TNNT2 and coronary artery disorder.